A Phase 1b/2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK, PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia Coli Pre-Transplant
Latest Information Update: 17 Jun 2025
At a glance
- Drugs SNIPR 001 (Primary) ; Levofloxacin
- Indications Escherichia coli infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors SNIPR Biome
Most Recent Events
- 12 Jun 2025 According to SNIPR Biome media release, company announced that first patient has been dosed in this trial.
- 21 May 2025 Planned number of patients changed to 24.
- 25 Apr 2025 Status changed from planning to recruiting.